Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of CMAB807X vs Xgeva in Healthy Males
NCT05808673Phase 1Withdrawn
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CMAB807 in solid tumor and Giant Cell Tumor of Bone (GCTB) (3 arms), sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoints: Area Under the Plasma Concentration-time Curve From Zero Hours Extrapolated to infinite time up to 3336 hours and Maximum Concentration of Denosumab up to 3336 hours. Planned start Feb 2023; status: withdrawn.
02
Drugs
CMAB807
03
Conditions
solid tumorGiant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT05808673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05808673.